Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
75.07
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
Next >
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
July 29, 2021
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues,...
Via
Talk Markets
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
July 29, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to...
Via
Benzinga
BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript
July 29, 2021
BMRN earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biomarin Pharmaceutical: Q2 Earnings Insights
July 28, 2021
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the...
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy
July 21, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from open-label Phase 1/2 trial of valoctocogene roxaparvovec, an investigational gene therapy...
Via
Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22
July 15, 2021
The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene...
Via
Benzinga
Exposures
Product Safety
EMA's Advisory Committee Backs Approval Of BioMarin's Dwarfism Candidate
June 25, 2021
European Medical Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of BioMarin...
Via
Benzinga
EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy
May 24, 2021
The European Medicines Agency (EMA) has granted its request for accelerated assessment review to BioMarin Pharmaceutical Inc’s (NASDAQ: BMRN)...
Via
Benzinga
Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit
May 19, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced an update to its previously reported results from Phase 1/2 study of valoctocogene roxaparvovec, an...
Via
Benzinga
Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript
April 29, 2021
BMRN earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biomarin Pharmaceutical: Q1 Earnings Insights
April 29, 2021
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 79.55...
Via
Benzinga
Preview: Biomarin Pharmaceutical's Earnings
April 28, 2021
Biomarin Pharmaceutical (NASDAQ:BMRN) releases its next round of earnings this Thursday, April 29. Here is Benzinga's essential guide to Biomarin Pharmaceutical's Q1 earnings...
Via
Benzinga
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.